Published in J Mol Med (Berl) on June 03, 2009
A new era of secreted phospholipase A₂. J Lipid Res (2015) 1.08
Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics. Anal Bioanal Chem (2011) 0.84
Secretory phospholipase A2 pathway in various types of lung injury in neonates and infants: a multicentre translational study. BMC Pediatr (2011) 0.79
The 763C>G Polymorphism of The Secretory PLA2IIa Gene Is Associated with Endometriosis in Iranian Women. Int J Fertil Steril (2015) 0.75
Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation (2005) 3.02
Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem (2008) 2.94
Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab (2004) 1.96
Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med (2007) 1.96
Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol (2007) 1.89
Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry (2007) 1.56
Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet (2002) 1.51
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation (1999) 1.50
A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb (1992) 1.45
Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation (2001) 1.44
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol (2005) 1.28
Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. J Biol Chem (1997) 1.28
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction. J Biol Chem (2006) 1.25
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem (2002) 1.22
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem (2008) 1.19
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol (2004) 1.18
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer (2008) 1.13
Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation (2008) 1.09
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology. J Biol Chem (2008) 1.08
Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta (2005) 1.06
Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim Biophys Acta (2005) 1.05
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum Mol Genet (2005) 1.05
On the binding preference of human groups IIA and X phospholipases A2 for membranes with anionic phospholipids. J Biol Chem (2002) 1.02
Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem J (2005) 1.00
Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis. Biochim Biophys Acta (2006) 0.99
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J (2006) 0.97
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. Hum Mol Genet (2007) 0.96
Neuronal expression and neuritogenic action of group X secreted phospholipase A2. J Biol Chem (2005) 0.95
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis. FEBS Lett (2000) 0.90
Neurotoxicity and other pharmacological activities of the snake venom phospholipase A2 OS2: the N-terminal region is more important than enzymatic activity. Biochemistry (2006) 0.89
The proinflammatory mediator Platelet Activating Factor is an effective substrate for human group X secreted phospholipase A2. Biochim Biophys Acta (2006) 0.84
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (2009) 11.81
Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. PLoS One (2010) 7.48
Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med (2009) 6.62
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81
Adhesion molecules and atherosclerosis. Atherosclerosis (2003) 3.68
Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation (2002) 3.20
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation (2005) 3.02
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation (2003) 2.89
A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature (2010) 2.88
Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med (2003) 2.87
Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation (2010) 2.84
Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood (2009) 2.64
Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA (2011) 2.61
Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation (2003) 2.26
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res (2005) 2.24
Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation (2008) 2.20
Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation (2002) 2.18
Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem (2011) 2.14
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost (2004) 2.09
Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol (2012) 2.02
Severe intraprocedural complications after transcatheter aortic valve implantation: calling for a heart team approach. Eur J Cardiothorac Surg (2013) 2.01
How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J (2012) 2.00
Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. Eur J Hum Genet (2005) 1.98
Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation (2011) 1.96
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat Genet (2011) 1.92
Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet (2010) 1.86
High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J (2013) 1.85
Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J (2008) 1.82
Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J Lipid Res (2010) 1.82
Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet (2009) 1.81
Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J (2010) 1.80
Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol (2010) 1.75
Polymorphisms of the beta2 -adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens (2002) 1.68
Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta (2013) 1.68
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67
Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care (2010) 1.66
Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J (2005) 1.65
A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet (2011) 1.63
Genetics of cardiovascular diseases: from single mutations to the whole genome. Circulation (2007) 1.60
Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J (2004) 1.58
Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions. Catheter Cardiovasc Interv (2013) 1.58
Family study of the relationship between height and cardiovascular risk factors in the STANISLAS cohort. Int J Epidemiol (2003) 1.58
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J (2008) 1.57
Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry (2007) 1.56
Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One (2010) 1.53